Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||BMS-986315 + Cetuximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BMS-986315||BMS 986315|BMS986315||BMS-986315 is a monoclonal antibody that binds to NKG2A and prevents its interaction with HLA-E, which may lead to cytotoxic immune response against tumor cells (NCI Thesaurus).|
|Cetuximab||Erbitux||IMC-C225||EGFR Antibody 39||Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04349267||Phase Ib/II||BMS-986315 + Cetuximab BMS-986315 BMS-986315 + Nivolumab||Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors||Recruiting||USA | CAN||3|